

Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com



Data Sheet PD-1 / NFAT - Reporter - Jurkat Recombinant Cell Line Catalog #: 60535

Product Description

Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human PD-1 (Programmed Cell Death 1, PDCD1, SLEB2, CD279, GenBank Accession #NM_005018).

Background

The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.

Application

- Screen for activators or inhibitors of PD-1 signaling in a cellular context
- Characterize the biological activity of PD-1 and its interactions with ligands

Format

Each vial contains 2 x 10⁶ cells in 1 ml of 10% DMSO

Storage

Immediately upon receipt, store in liquid nitrogen.

Mycoplasma Testing

The cell line has been screened using the PCR-based Venor[®]GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of *Mycoplasma* species.

General Culture Conditions

Thaw Medium 2 (BPS Cat. #60184): RPMI1640 medium (Life Technologies #A10491-01) supplemented with 10% FBS (Life Technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone #SV30010.01).

Growth Medium 2A (BPS Cat. #60190): Thaw Medium 2 (BPS Cat. #60184), 1 mg/ml of Geneticin (Life Technologies #11811031), and 200 μ g/ml of Hygromycin B (Hyclone #SV30070.01).

Cells should be grown at 37° C with 5% CO₂ using Growth Medium 2A (Thaw Medium 2, Geneticin, and Hygromycin B).



To thaw the cells, it is recommended to quickly thaw the frozen cells from liquid nitrogen in a 37° C water-bath, then transfer the entire contents of the vial to a tube containing 10 ml of Thaw Medium 2 (no Geneticin and Hygromycin B). Spin down the cells, remove supernatant and resuspend cells in pre-warmed Thaw Medium 2 (no Geneticin and Hygromycin B). Transfer the resuspended cells to a T25 flask and incubate at 37° C in a 5% CO₂ incubator. This cell line tends to grow more slowly than parental Jurkat cells. After 24 hours of culture, add an additional 3 - 4 ml of growth medium without antibiotics. At first passage, switch to Growth Medium 2A (contains Geneticin and Hygromycin B). Cells should be split before they reach $2x10^{6}$ cells/ml.

To passage the cells, dilute cell suspension into new culture vessels at no less than 0.2x10⁶ cells/ml. Subcultivation ratio: 1:10 to 1:20 twice a week.


Functional Validation and Assay Performance

Expression of human PD-1 in Jurkat cell line was confirmed by Western blotting.

The functionality of the cell line was validated using a PD-1:PD-L1 (or PD-L2) cell-based assay. In this assay, PD-1/NFAT Reporter/Jurkat T cells are used as effector cells; HEK293 or CHO cells over-expressing PD-L1 (or PD-L2) and an engineered T cell receptor (TCR) activator are used as target cells. When these two cells are co-cultivated, TCR complexes on effector cells are activated by TCR activator on target cells, resulting in expression of the NFAT luciferase reporter. However, PD1 and PD-L1 (or PD-L2) ligation prevents TCR activation and suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti-PD1 or anti-PD-L1 antibodies. PD1/PD-L1 neutralizing antibodies block PD1:PD-L1 interaction and promote T cell activation, resulting in reactivation of the NFAT responsive luciferase reporter.



Assay Principle



Materials Required but Not Supplied

- TCR-activator PD-L1 CHO cell line (BPS Cat.#60536)
- Assay medium: Thaw Medium 2 (BPS Cat. #60184)
- Growth Medium 2A (BPS Cat. #60190)
- Anti-PD-1 neutralizing antibody: BPS bioscience #71120
- Anti-PD-L1 neutralizing antibody: BPS bioscience #71213
- 96-well tissue culture-treated white clear-bottom assay plate
- One-Step luciferase assay system (BPS bioscience # 60690) or other luciferase reagents for measuring firefly luciferase activity
- Luminometer
- Thaw Medium 3 (BPS Cat. #60186): Ham's F-12 medium (Hyclone # SH30526.01) supplemented with 10% FBS (Life technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone SV30010.01).



Protocol

- Harvest TCR activator / PD-L1-CHO cells from culture and seed cells at a density of 35,000 cells per well into white clear-bottom 96-well microplate in 100 µl of Thaw Medium 3, BPS Cat. #60186 (growth medium without Geneticin and Hygromycin B). Incubate cells at 37° in a CO2 incubator for overnight. Cells should reach ~80% confluency on the next day (cells should not reach confluency in this step).
- Next day, prepare serial dilution of anti-PD-1 antibody or anti-PD-L1 antibody in assay medium (Thaw Medium 2, BPS Cat. #60184) (the concentration of antibody here is 2x of the final treatment concentration of antibody). Harvest the PD-1/NFAT-reporter-Jurkat cells by centrifugation and resuspend in assay medium. Dilute cells to 4x10⁵ / ml in assay medium.

To test anti-PD-1 antibody, preincubate the PD-1/NFAT Reporter- Jurkat cells (4x10⁵ / ml) with diluted anti-PD-1 antibody (1:1 in volume) for 30 min. After incubation, remove the medium from TCR activator/PD-L1-CHO cells and add 100 µl of PD-1/NFAT reporter – Jurkat cells / anti-PD-1 antibody mixture to the wells. (Note: *Mix the PD-1/NFAT Reporter- Jurkat cells with antibody well before adding to TCR activator/PD-L1-CHO cells*.)

To test the anti-PD-L1 antibody, remove the medium from TCR activator/PD-L1-CHO cells, add 50 μ I of diluted anti-PD-L1 antibody to the wells and incubate for 30 min. After incubation, add 50 μ I of PD-1/NFAT Reporter- Jurkat cells (4x10⁵ / mI) to the wells. (Note: *Mix the PD-1/NFAT Reporter- Jurkat cells well before adding to TCR activator/PD-L1-CHO cells.*)

Final cell density of PD-1/NFAT Reporter- Jurkat cells is 2 x10⁴ /well. Set up each treatment in at least triplicate.

Add 100 μ l of assay medium to cell-free control wells (for determining background luminescence).

Incubate the plates at 37° in a CO2 incubator for 5 to 6 hours.

- 3. After ~5 to 6 hour incubation, perform luciferase assay using the ONE-Step luciferase assay system: Add 100 µl of One-Step Luciferase reagent per well and rock gently at room temperature for ~30 minutes. Measure luminescence using a luminometer.
- OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. To place your order, please contact us by Phone **1.858.829.3082** Fax **1.858.481.8694** Or you can Email us at: <u>info@bpsbioscience.com</u> Please visit our website at: <u>www.bpsbioscience.com</u>




If using luciferase reagents from other vendors, follow the manufacturer's assay protocol.

 Data Analysis: Subtract the average background luminescence (cell-free control wells) from the luminescence reading of all wells. The fold induction of NFAT luciferase reporter expression = background-subtracted luminescence of treated well / average background-subtracted luminescence of untreated control wells.

Figure 1. Cell Characterization Using a PD-1 Neutralizing Antibody. TCR activator/PD-L1-CHO cells were seeded in 96-well plate. The next day, TCR activator/PD-L1-CHO cells were incubated with anti-PD-1 neutralizing antibody (BPS Cat. #71120) and PD-1/NFAT Reporter-Jurkat cells (BPS Cat. #60535) (or control NFAT Reporter – Jurkat cells, BPS Cat. #60621). After incubation, ONE-Step[™] Luciferase reagent (BPS Cat. #60690) was added to the cells to measure NFAT activity.

The fold induction is equal to background-subtracted luminescence of antibody-treated well/background-subtracted luminescence of untreated-control wells of each respective cell line.

A. Anti-PD-1 neutralizing antibody induced NFAT luciferase reporter activity in PD-1/NFAT Reporter-Jurkat cells, but not NFAT Reporter – Jurkat cells, co-cultured with TCR activator/PD-L1-CHO cells.





B. Dose response of anti-PD-1 neutralizing antibody in PD-1/NFAT Reporter-Jurkat cells





Figure 2. Cell Characterization Using a PD-L1 Neutralizing Antibody TCR activator/PD-L1-CHO cells were seeded in 96-well plate. The next day, TCR activator/PD-L1-CHO cells were incubated with anti-PD-L1 neutralizing antibody (BPS Cat. #71213) and PD-1/NFAT Reporter-Jurkat cells (BPS Cat. # 60535) (or control NFAT Reporter – Jurkat cells, BPS Cat. #60621). After incubation, ONE-StepTM Luciferase reagent (BPS Cat. #60690) was added to cells to measure NFAT activity.

The fold induction is equal to background-subtracted luminescence of antibody-treated well / background-subtracted luminescence of untreated-control wells of each respective cell line.

A. Anti-PD-L1 neutralizing antibody induced NFAT luciferase reporter activity in PD-1/NFAT Reporter-Jurkat cells, but not NFAT Reporter – Jurkat cells, co-cultured with TCR activator / PD-L1 – CHO cells.



6042 Cornerstone Court W, Ste B San Diego, CA 92121 **Tel:** 1.858.829.3082 **Fax:** 1.858.481.8694 **Email:** info@bpsbioscience.com



B. Dose response curve of anti-PD-L1 neutralizing antibody in PD-1/NFAT Reporter-Jurkat cells





Figure 3. FACS analysis of cell surface expression of PD-1 in PD-1/NFAT Reporter-Jurkat cells.

PD-1/NFAT Reporter-Jurkat cells or control NFAT Reporter-Jurkat cells were stained with PElabeled anti-PD-1 antibody (BPS Cat # 71290) and analyzed by FACS. Y-axis is the cell count. X-axis is the intensity of PE.





Samples	Cell Count
NFAT reporter-Jurkat	28165
PD-1/NFAT-Jurkat	27005

Sequence

hPD-1 sequence (accession number NM_005018)

MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFV LNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISL APKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVIC SRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSG MGTSSPARRGSADGPRSAQPLRPEDGHCSWPL

Related Products

Product	Cat. #	Size		
NFAT Reporter – Jurkat cell line	60621	2 vials		
TCR-activator CHO PD-L1 cell line	60536	2 vials		
Anti-PD-1 neutralizing antibody	71120	100 µg		
Anti-PD-L1 neutralizing antibody	71213	100 µg		
ONE-Step™ Luciferase Assay System	60690-1	10 ml		
ONE-Step [™] Luciferase Assay System	60690-2	100 ml		
Anti-PD-1 Antibody, PE-labeled	71290-1	50 µg		
Anti-PD-1 Antibody, PE-labeled	71290-2	100 µg		
Human PD-1 (CD279), Fc fusion	71106	100 µg		
Human PD-1, FLAG-Avi-His-tag	71198	50 µg		
OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.				
To place your order, please contact us by Phone 1.858.829.3082 Fax 1.858.481.8694				
Or you can Email us at: info@bpsbioscience.com				
Please visit our website at: <u>www.bpsbioscience.com</u>				



Human PD-L1 (CD274), Fc fusion	71104-1	50 µg
Human PD-L1 (CD274), Fc fusion	71104-2	100 µg
Human PD-L1 (CD274), FLAG-Avi-His tag	71183	50 µg
Human PD-L2 (CD273), Fc fusion	71107	100 µg
Human PD-1, Fc fusion, Biotin-labeled	71109	50 µg
Human PD-L1, Fc fusion, Biotin-labeled	71105	50 μg 50 μg

Notes

License Disclosure: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact sales@bpsbioscience.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.